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ABSTRACT: C-methylation of aromatic small molecules by C-
methyltransferases (C-MTs) is an important biological trans-
formation that involves C-C bond formation using S-adenosyl-
L-methionine (SAM) as the methyl donor.  Here, two advances 
in the mechanistic understanding of C-methylation of the 8-po-
sition of coumarin substrates catalyzed by the C-MT NovO 
from Streptomyces Spheroides are described.  First, a crystal 
structure of NovO reveals the Arg116-Asn117 and His120-Arg121 
motifs are essential for coumarin substrate binding. Second, the 
active-site His120 is responsible for deprotonation of the phe-
nolic 7-hydroxyl group on the coumarin substrate, activating 
the rate-determining methyl transfer step from SAM. This work 
expands our mechanistic knowledge of C-MTs which could be 
used in the downstream development of engineered biocatalysts 
for small molecule C-alkylations. 
Methylation is an essential biological transformation used 
throughout Nature. This process is catalyzed by the 
methyltransferase (MT) family of enzymes and is used to 
control key biological processes, from gene regulation and 
epigenetics via histone lysine N-MTs,1Ȃ3 through to key methyl 
transfer steps in the biosynthesis of vitamins B12 and E.4,5 This 
family of enzymes catalyze O-, N, C- and even S-methylation 
of biomacromolecules and small molecule natural products 
(NPs) using S-adenosyl-L-methionine (SAM) as the methyl 
donor.6Ȃ9 Of the various types of biocatalytic methylation 
reactions catalyzed by MTs, C-methylation has gained 
considerable prominence as a key epigenetic regulator of gene 
expression by methylating the 5-position of cytosine catalyzed 
by DNA m5C MTs. The mechanism of C-methylation of DNA 
by m5C MTs occurs via initial thiolation of the C6-position of 
cytosine by an active site cysteine residue, methylation using 
SAM as the methyl donor at the C5-position and finally 
deprotonation/dethiolation to reestablish the pyrimidine 
aromatic system.10,11 
In contrast to numerous MTs that catalyze the SAM-
dependent C-methylation to protein and nucleic acid 
substrates, fewer than ten NP C-MTs have been reported; the 
majority of which have not been structurally and 
mechanistically characterised.12Ȃ15 One exemplar is the C-MT 
NovO, which catalyses the regiospecific C-methylation of 
aminocoumarin 1 at the 8-position to form 2; an intermediate 
in the biosynthesis of the antibiotic novobiocin 3 by 
Streptomyces Spheroides (Scheme 1a).16,17 Work by Gruber et 
al. has shown that NovO catalyses the alkylation of 
aminocoumarin substrate analogues to provide products 4a-c 
and dihydroxynapthalene 5 using SAM (Scheme 1b) and non-
natural SAM analogues bearing a variety of alkyl groups, 
which opens up opportunities to undergo Friedel-Crafts-like 
C-alkylations on high value small molecule substrates.18 
Although this study provided initial insight into the substrate 
scope of NovO, a detailed understanding of the structure of 
this NP-MT and the factors associated with substrate 
recognition and the catalytic mechanism of methyl transfer 
are not known. Furthermore, NovO displays only 10-15% 
sequence homology with other structurally characterized NP-
MTs in the Protein Data Bank (PDB, Figure S1), and as such it 
is difficult to gain accurate structural and mechanistic insight 
from homology models.12,13 In this paper, we report a detailed 
structural and functional study of NovO. Using a combination 
of crystal structure analysis, substrate docking, site directed 
mutagenesis, kinetic isotope effect (KIE) studies and  
substrate  analogue  screens, we show that NovO uses a 
 
Scheme 1. (a) SAM-dependent methyl transfer catalyzed by 
NovO in the biosynthesis of novobiocin by Streptomyces 
Spheroides. (b) Non-natural product analogues accessible 
with NovO.18 
novel His-Arg motif firstly to deprotonate (His) the phenolic 
OH in the 7-position of substrate 6, and then to lock (Arg) the 
 substrate in place for C-methylation to occur exclusively at the 
8-position by SAM. 
The X-ray crystal structure of selenomethionine (SelMet) 
substituted NovO in complex with S-adenosylhomocysteine 
(SAH) was determined by single-wavelength anomalous 
dispersion.  NovO crystallized as a homodimer, in which each 
monomer contains the characteristic Rossmann fold found 
extensively in SAM-dependent MTs.19,20 This result is 
consistent with a previous report from Gruber et al. that NovO 
is active as a dimer in solution.21 The contact interface consists 
of two C-Ʉ-helices (Figure 1a, shown in blue) with 
an average separation of 2.85 Å. This is atypical for Class I MTs, 
Ʉ-helices at the N-terminus.20 
Although NovO displays very low sequence homology to other 
structurally characterised NP-MTs, a search for close 
structural analogues within the PDB revealed the 
carboxymethyl-SAM RNA MT CmoA and YecO from 
Haemophilus influenzae to be the closest analogues with 88% 
and 83% structural similarity, respectively.22Ȃ24 The residues 
forming the SAH binding pocket are located at flexible regions 
(Figure 1aǡ   Ȍ  Ʉ-  Ʌ-
sheets.19,20 Extensive H-bonding networks are formed between 
the SAH-carboxylate and R116; the adenine-NH2 and the two 
acidic residues E4 and D96; and the two ribose-hydroxyl 
groups with D70 (Figure 1b and Figure S4). Whilst D96 and 
D70 are both highly conserved across the Class 1 MT family, 
the other residues involved in SAH binding vary across the 
class (Figure S1). Another feature common to Class 1 MTs is a 
 ǡ      Ǯ  ?ǯ
consisting of E/DXXXGXG, where X is any residue.19Ȃ21 Gruber 
et al. have previously proposed this motif  
(a) 
(b)  
  
Figure 1. Crystal structure of NovO (PDB accession code: 
5MGZ) (a) complexed with SAH (coloured in orange) and (b) 
Ǯ ?ǯȋ ? ?ǡ
L46, C47, C48, G49, S50, G51). 
was located between D45 and G51, with D45 and G49 being 
crucial for enzymatic function, and C47, C48, G51 and D70 
critical for protein folding. With reference to our crystal 
structure, D45 does indeed make key hydrogen bonds with the 
amino acid moiety of SAH via two water molecules (Figure 
1b). Analysis of the protein structure by B-value revealed 
Arg24 to be highly flexible with an average B-factor of ~32, 
compared to that of ~16 for surrounding residues (Figure S5), 
and further confirmed by the existence of two conformations 
in the crystal structure. Given its positioning at the solvent 
interface, proximity to the active site and the absence of a pore 
for entrance of substrate to the active site, we surmise that this 
residue plays a gatekeeper role as has previously been 
described for some structurally unrelated peroxidases.25 
Although attempts to obtain a crystal structure of NovO in 
complex with aminocoumarin substrate 618 and SAM, SAM 
analogues26,27 or S-adenosylhomocysteine (SAH) were 
unsuccessful, a model was generated using Molecular 
Operating Environment (MOE) software28 using the crystal 
structure of the NovO-SAH complex to investigate the 
binding of 6 in NovO (see Supporting Information). A set of 6 
residues were identified as putative active site residues 
(Figure 2). In particular, H120 and R121 made key hydrogen 
bond contacts with the phenolic group in the 7-position and 
R116 and N117 with the coumarin lactone. To the best of our 
knowledge, this is the first time that these two motifs have 
been implicated in a MT binding pocket. Furthermore, this 
model accounted for the experimentally observed 
regiospecificity of methyl transfer for the 8-position of the 
coumarin ring, as C-8 is positioned directly above the sulfur 
centre of SAH. This was confirmed by modelling a methyl 
group onto the SAH to mimic the naturally-occurring 
diastereomer (S-) of SAM (Figures S6 and S7).  
 
   
Figure 2. Substrate docking model of aminocoumarin 6 
(green) in the crystal structure of NovO complexed with SAH. 
In order to test the validity of our model, we probed the 
function of each of these residues by site-directed 
mutagenesis (SDM). A suite of systematic mutations were 
prepared to probe the electronic environment of the proposed 
substrate pocket and where possible, maintain a similar steric 
environment by mutating residues of a similar size. 
Furthermore, we investigated the significance of R24 as the 
proposed gatekeeper residue by its replacement with 
(c) 
(a) 
 phenylalanine, which was hypothesised to inhibit entrance to 
the active site.25 The catalytic activity of each mutant was 
measured by conversion to the corresponding methylated 
product 4a after 24 hours (Figure 3a).18,21 All mutants resulted 
in a significant decrease in MT activity, with complete 
abolition of activity for mutants at positions R116, N117, H120 
and R121.  
These observations were consistent with our substrate 
binding model in which F14 takes part in end-ɕ-stacking 
interactions with the coumarin lactone ring and Y216 donates 
an H-bond to the amide carbonyl group (Figure 2). Whilst 
these residues are proposed to be involved in substrate 
binding, they are not essential for enzyme function as 
observed by a low level of conversion to product 4a.  
Conversely, H120 and R121 form H-bonds with the hydroxy 
group adjacent to the site of methylation.  
(a) 
 
(b) 
 
Figure 3. (a) Percentage (%) methylation of substrate 6 to 
provide product 4a after 24 hours by NovO WT relative to 
NovO mutants. * Due to the low levels of soluble expression 
of H120A, cell lysate was used. (b) Enzymatic activity of C-
methylation of 6 by NovO H120K and R121K mutants relative 
to WT over pH values 5-8. 
Based on these mutagenesis studies, we hypothesized that 
both H120 and R121 are essential for substrate activation, 
which was further probed by two single point mutants H120K 
and R121K. Whilst protonated R121K would be expected to 
support an H-bond to the phenolic hydroxy group in a similar 
manner to R121, H120K would most likely be protonated under 
the assay conditions and could not act as an appropriate base 
in order to activate the coumarin substrate 6 towards 
electrophilic aromatic substitution. As shown in Figure 3b, 
the H120K mutant was inactive across a pH range 5-7, whilst 
R121K retained ~20% of the activity displayed by the WT above 
pH 6.5. Further analysis of the NovO crystal structure around 
the R121 residue revealed an extensive H-bonding network 
between the guanidinium moiety and nearby residues directly 
and via water molecules (Figure S9).  Thus, the formation of 
a sub-optimal H-bond network in the R121K mutant could 
explain the lower catalytic activity observed for the C-
methylation of 6 between pH 6.5-8. When the pH was below 
6.5, a drop off in C-methylation activity was observed, which 
aligns with the pKa of protonated histidine. With reference to 
this and the crystal structure, we conclude that the H120- R121 
motif plays an essential role in C-methylation of 6. To the best 
of our knowledge, this is the first time that such a motif has 
been implicated in methyl transfer by Class I MTs.12,13,21 This 
result is in contrast to a homology model of NovO reported by 
Gruber et al. (Figure S11a), in which H15 was hypothesised to 
be the catalytic base.21 When the position of this residue is 
identified in our crystal structure, it is seen to be at the solvent 
interface rather than in the substrate binding pocket (Figure 
S11b).  
Next, the role of the hydroxy group at the 7-position of the 
coumarin scaffold was investigated. A library of substrate 
analogues was prepared with electron withdrawing 
(substrates 7-Cl S1 and 7-NO2 S2 or an electron donating 
group (substrate ȂNH2 S3, -OMe S4) in the 7-position 
(Scheme S2). These analogues were screened under the 
standard assay conditions with the WT enzyme (Scheme S1). 
In all cases, no methylation was detected by HPLC after 24 
hours, which indicates that the hydroxy group in the 7-
position of 6 is essential for catalysis.18 
To better understand the nature of the transition state and 
rate limiting step of C-methylation of 6, primary and 
secondary KIEs were determined using purified NovO and 
SAM or the isotopic analogues 13CH3-SAM and CD3-SAM.. 
Whilst with NovO exhibited a kcat of 20.1x10-3 s-1 using SAM as 
the methyl donor,17,18 a kcat of 17.0x10-3 s-1 was measured using 
13CH3-SAM resulting in a primary KIE of 1.22. This value is 
notably higher than the primary KIEs for catachol O-MT 
(COMT)29 and human DNMT111 reported by Schowen and 
Schramm, respectively. However, NovO represents a 
mechanistically distinct small molecule C-MT and to the best 
of our knowledge, this is the first report of KIE data for this 
class of MT. This KIE is  indicative of methyl transfer being the 
rate limiting step in the catalytic cycle, as has been reported 
for COMT.30 Furthermore, a large, normal KIE is characteristic 
of a symmetric transition state in the SN2 reaction.30Ȃ33 A kcat 
of 20.1x10-3 s-1 was measured when CD3-SAM was used, giving 
a smaller secondary KIE value of 1.03, which was within the 
limits of the error margins (Table 1 and Figure S10) and 
therefore not statistically significant. 
Table 1. Kinetic Parameters and KIE values. 
 Km (µM) kcat (s
-1) KIE 
Me-SAM 43.7 (±2.8) 2.1x10-3 (±0.0004) - 
13CH3-SAM 41.6 (±5.1) 1.7x10
-3 (±0.0008) 1.22 (±0.04) 
CD3-SAM 52.8 (±5.3) 2.0x10
-3 (±0.0009) 1.03 (±0.03) 
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Scheme 2. Proposed mechanism of C-methylation of substrate 6 by NovO. 
Taken collectively, we propose the following catalytic 
mechanism of C-methylation by NovO (Scheme 2). An initial 
enzyme-substrate complex is formed through H- bonding of 
the C-2 carbonyl of coumarin 6 with R116 and N117.  Based on 
the pKa of histidine and the proximity of H120 to the phenolic 
proton (~1.75 Å based on the substrate docking model in 
Figure 2) and our study of mutants H120K and R121K, H120 
deprotonates the phenolic -OH in the 7- position. The 
resulting phenoxide is stabilized by H-bonding to protonated 
H120 and R121 and has sufficient nucleophilicity to effect 
electrophilic aromatic substitution at the 8-position by SAM 
as the methyl donor. Following deprotonation, it is also 
possible that the phenolic anion is stabilised by Arg116 and 
Asn117 as loss of activity was also observed when these 
residues were mutated. Finally, rapid deprotonation of the 
resulting intermediate to regain aromaticity of the system 
provides the enzyme-product complex.  
In summary, we have shown that C-methylation of coumarin 
6 proceeds be a novel mechanism catalysed by NovO.12,13,15  The 
His120-R121 motif is critical for substrate activation and 
docking of the coumarin substrate 6 into the active site of 
NovO. To the best of our knowledge, this is the first example 
of an His-Arg motif being implicated in the key stage of 
methyl transfer by a MT. Furthermore, our substrate analogue 
library reveals the 7-position hydroxy group is essential for 
substrate activation, rendering the aromatic ring susceptible 
to the rate-determining electrophilic aromatic substitution 
step at the 8-position.  We envisage that this work will assist 
in the engineering of NovO variants that could be used in the 
development of a platform technology for biocatalytic C-
alkylation of small molecule substrates. 
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1 Sequence alignment of small molecule aromatic C-MTs and BLAST results 
Sequence alignment carried out using MOE software (Figure S1).1 In addition to analyses of other 
small molecule aromatic C-MTs, the top two hits from a Basic Local Alignment Search Tool 
(BLAST) are shown in Figure S1 (entries 10 and 11). UniProt identifiers A0A017T191_9DELT and  
NAL212_0227). 
 
 
Figure S1. Sequence alignment of small molecule aromatic C-MTs (entries 2-9) and top two BLAST hits for NovO in 
UniProt (entries 10-11). Results coloured according to amino acid similarity (blue: high; red: low). 
2 Determination of SelMet NovO crystal structure 
Crystallisation of NovO with SAH  
C-terminal His-tagged NovO 1-230 from Streptomyces spheroides at 12 mg/mL in 0.1 M 
trisaminomethane hydrochloride (Tris-HCl) pH 8.0, 150 mM NaCl was incubated with 2 mM S-
adenosylhomocysteine (SAH) and left on ice for 30 minutes. Microseeding was used to obtain 
reproducible SelMet crystals of good quality. Crystallisation was achieved using drops containing 
120 nL protein, 120 nL well solution (0.1 M 2-[N-morpholino]ethanesulfonic acid, [MES] pH 6.5, 
20% w/v poly[ethylene glycol] [PEG]-4K, 0.6 M NaCl)  and 60 nL seed solution in sitting drop 
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Medical Research Council (MRC) plates at 20 °C. Crystals grew over a period of 18 days and were 
harvested into mother liquor supplemented with 15% glycerol before flash freezing. 
 
Data collection, Structure solution and refinement 
 X-ray diffraction data were collected at 100 K at the European Synchrotron Radiation Facility 
(ESRF, beamline ID23.1). Selenomethionine (SelMet) datasets were collected at the SelMet 
absorption peak (0.97916 Å fƍ= -7.82, fƍƍ= 4.98), 1800 images taken with 0.2 degree oscillations to 
give 360 degrees in total. The data were processed and scaled using autoPROC.2 As there was no 
known structure of NovO the structure was solved by Single-wavelength Anomalous Dispersion 
(SAD). AUTOSHARP3 and CCP44  were used for heavy atom detection, refinement, phasing and 
density modification. Two molecules of a homodimer were present within the asymmetric unit of the 
P21 crystal, with a solvent fraction of 45.3%. All 12 SelMet sites were found. The autobuilt 
coordinates provided a good starting point for manual rebuilding of NovO using COOT.5 Structure 
refinement was carried out using AUTOBUSTER6 utilising TLS refinement and automatic water 
fitting, with additional round of refinement and modelling were achieved using COOT and refmac7 
with TLS refinement. The S-adenosylhomocysteine (SAH) was present in the active site of both 
chains (Figures S2-S3). MOGUL and MOLPROBITY were used to confirm the quality of the refined 
structure. Refinement statistics of the 1.9 Å X-ray homodimeric complex of NovO with SAH are in 
Table S1. PDB accession code: 5MGZ. 
Crystallography Omit Maps 
  
 
  
Chain A Chain B 
 
Figure S2. Omit (Fo-Fc) map of SAH in the active site contoured at ±3sigma (blue/red), ±9sigma 
(purple/orange). Conformation for the SAH is well defined. 
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Chain A Chain B 
            
Figure S3. Omit (2Fo-Fc) map of SAH in the active site contoured at +1sigma (blue), +3sigma (purple). 
Conformation for the SAH is well defined. 
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Table S1:  Data collection and refinement statistics 
(collection on a single crystal) NovO/SAH 
 
Data collection  
 
Space group P21  
Cell dimensions 
 
 
    a, b, c (Å) 43.724, 66.970, 80.563  
DEJ (q)  90.000, 92.99, 90.000  
Resolution (Å) 66.97-1.90 (2.00-1.90) 
 
 
Rmerge 0.056 (0.080)  
I/VI 22.6 (10.6)  
Mn(I) CC (1/2) 0.997 (0.988)  
Anomalous completeness (%) 88.6 (53.2)  
Completeness (%) 90.7 (58.0)          
Anomalous multiplicity 3.0 (1.8)  
Redundancy 6.0 (3.8)  
Wilson B-factor 17.79  
 
 
 
Refinement 
 
 
Resolution (Å) 66.97-1.90  
No. reflections 201009 (11593)  
No. uniq reflections 33239 (3062)  
Rwork/ Rfree 0.178/0.202  
No. atoms 4330  
    Protein 3618  
    Ligand/Other 52/10  
    Water 650 
 
 
Ramachandran 
 
 
    Favored (%)  97  
    Allowed (%) 3  
    Outliers (%) 0.22  
    Rotamer outliers 0.54  
B-factors 
 
 
    Protein 23.24  
    Ligand/Other 11.13/26.50  
    Water 31.68  
R.m.s deviations 
 
 
    Bond lengths (Å)  0.005  
    Bond angles (º) 1.032  
*Highest resolution shell is shown in parenthesis 
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3 S-adenosylhomocysteine (SAH) binding site 
  
Figure S4. Interaction diagram of SAH binding site generated using Molecular Operating Environment1 software. 
 
4 Analysis of NovO by B-factor to reveal flexible R24 
 
 
 
 
 
 
Figure S5. (a) Analysis of R24 by B-factor. Two conformations were visible in the X-ray crystal structure. SAH is shown in 
grey. (b) Surface of NovO (Chain A only) coloured by B-factor. Colour scale: Blue (low) ± white ± red (high). 
Arg24 
 
SAH 
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5 Preparation of substrate binding model 
The substrate binding model was generated using Molecular Operating Environment (MOE)1 
software. The X-ray crystal structure was prepared using the Stucture Preparation command followed 
by optimisation of the H-bonding network using the Protonate 3D8 (pH 7) command, and finally 
calculation of partial charges. Putative binding sites in NovO were identified using the Site Finder 
application.9,10 The default settings for these procedures were used in all cases and SAH was retained 
in the crystal structure throughout the study (Table S1).  
Table S1. Top 5 ligand binding sites identified by the Site Finder application using MOE. PLB: propensity for ligand 
binding.10 
The putative binding sites were further analysed manually based on their proximity to the SAH 
present in the crystal structure. Site 1 was found to be in a suitable location relative to SAH (Figure 
S5).  
 
1. 
 
Site PLB Residues 
1 3.6 
 
I6, F14, M17, G18, Q20, A21, H23, R24, Y25, R116, N117, A118, H120, R121, 
F127, F164, Q167, R168, P169, W170, D171, M174, V177, W178, A181, Y216. 
2 1.05 
 
 
 
M1, K2, I3, E4, A6, I6, T7, E10, A11, H120, R121, I176, V177, L180, A181, W184, 
A185 
3 1.05 
 
 
 
 
E155, R159 (Chain 1), M1, K2, I3, E4, A6, I6, T7, E10, A11, H120, R121, I176, 
V177, L180, A181, W184, A185 (Chain 2) 
4 0.77 
 
 
 
 
K2, F119, H120, L122, T123, R124, L125, P126, Y184, A185, P186, D190, E193, 
A194, Q197 
5 0.13 
 
 
 
K2, L122, T123, R124, L125, P126, Y184, A185, P186, D190, E193, A194 
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2. 3. 
4. 5. 
Figure S5. Top 5 results from Site Finder search using MOE software relative to the position of SAH, which is shown in 
orange. Dummy atoms are represented as white and red spheres.  
The Dock application was employed to model substrate 6 into the putative binding site. The top 5 hits 
were analysed manually and the final model selected based on proximity of the coumarin C-8 to the 
sulfur centre of SAH and the potential energy of the substrate, giving rise to the final model shown in 
Figure S6, in which the coumarin ring was adopted a planar conformation. When a methyl group was 
modeled onto the sulfur centre of SAH to model the naturally occurring, S- diastereomer of SAM,11 
the pendant methyl group was 2.59 Å from C-8, at an angle of 109 ° from the coumarin scaffold. 
 
Figure S6. Conformation of substrate 6 in substrate binding model distance between coumarin C-8 and the SAM methyl 
group. 
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Figure S7. Substrate 4a (shown in green) docking model with SAM (shown in orange) modelled into the active site of NovO 
by addition of a methyl group and subsequent minimisation of the sulfonium center. The stereochemistry (-S) at the 
sulfonium center corresponds to the natural diastereoisomer of SAM. 
6 Environment surrounding H120 and R121 
 
Figure S8. H-bonding network of the NovO active site residues H120. 
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Figure S9. H-bonding network of the NovO active site residues R121. 
7 Analysis of substrate analogues with variation at the 7-position 
A suite of analogues of substrate 6 were prepared (see Scheme S2) and was used to the explore the 
enzymatic activity of NovO (see Section 12). All substrate analogues were inactive with NovO WT 
(Scheme S1). 
 
Scheme S1. Methylation of aminocoumarin substrates 6 and S1-S4 to products 4a and S5-S8 by NovO WT. Reagents and 
conditions: (a) NovO, SAM, bovine serum albumin, 50 mM sodium phosphate buffer pH 6.5, 35 °C, 24 h. See Section 12. 
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8 Kinetic Isotope Effect (KIE) Data 
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Figure S10. Michealis Menten curves for KIE data for NovO WT. The data set was collected accorded to the procedure 
outlined in Section 11 using purified NovO and SalL. The data set was processed using Origin12 software, using the 
Michealis Menton Nonlinear Curve Fit function. Reagents and conditions: (a) methionine, (2R,3R,4S,5S)-2-(6-amino-9H-
purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3,4-diol (S35), SalL13,14, potassium phophate buffer (50 mM, pH 6.5), 37 °C, 2 
hours, then NovO. See Section 11. 
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9 Comparative analysis of homology model of NovO with the X-ray crystal 
structure of NovO and SAH 
A homology model of the active site of NovO, based on the SAM-dependent MT from Pyrococcus 
horikoshii OT3 (PDB code 1WZN) has previously been disclosed by Tengg et al.15 The positions of 
putative active site residues H15 and Y184 in this model were compared to their positions in the 
crystal structure of NovO (Figure S). 
              
Figure S11. (a) Homology model of NovO with bound SAH based on the SAM-dependent MT derived from Pyrococcus 
horikoshii OT3 (PDB code 1WZN) as proposed by Tengg et al.15 Model generated using Yasara software.10 (b) Position of 
H15 and Y184 in NovO relative to the substrate and SAH according to the substrate binding model generated from our 
crystal structure of NovO. 
10 Synthesis of aminocoumarin substrates 
General experimental techniques and procedures 
All reagents and solvents were used as supplied from commercial sources and used without further 
purification unless otherwise stated. Solvents used in the preparation of substrates 7-10 were all High 
Pressure Liquid Chromatography (HPLC) grade and were used without further purification unless 
otherwise stated. Nuclear Magnetic Resonance (NMR) spectroscopy was carried out using a Bruker 
8OWUD6KLHOG%-ACS 60 spectrometer. All chemical shifts (G) were referenced to the deuterium 
lock and are reported in parts per million (ppm) and coupling constants are quoted in hertz (Hz). 
Abbreviations for splitting patterns are br. (broad), app. (apparent), s (singlet), d (doublet), t (triplet), 
q (quartet), m (multiplet) and dd (doublet of doublets). All NMR data was processed using Advanced 
Chemistry Development Inc. (ACD/Labs) 12.0 software.16 Proton and carbon chemical shifts were 
assigned using proton (1H), carbon (13C), Heteronuclear Single Quantum Coherence (HSQC), 
Heteronuclear Multiple-Bond Correlation Spectroscopy (HMBC), Correlation Spectroscopy (COSY) 
Y184 
H15 
(a) (b) 
SAH 
Substrate 6 
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and Distortionless Enhancement of Polarisation Transfer (DEPT). Liquid Chromatography coupled 
Mass Spectrometry (LC-MS) was carried out on an Agilent 1100 HPLC instrument in conjunction 
with a Waters Micromass ZQ 2000/4000 mass detector. Electrospray ionization (ESI) was used in all 
cases. HPLC was carried out on an Agilent 1100 series instrument. Infra-Red (IR) data was collected 
on a Perkin Elmer Spectrum One FTIR spectrometer and the data was processed using Spectrum One 
software. Only major absorbances are reported. Melting points of solids were obtained using a Stuart 
automatic SMP40 melting point machine  or a SRS OptiMelt automated melting point system. 
Synthesis of aminocoumarin substrates 
Aminocoumarin substrates and variants based on substitution at the 7- position were synthesised by a 
modified route outlined by Gruber et al. (Scheme S2).17 
 
Scheme S2. Synthetic route to aminocoumarin substrates 6 and S1-S4.17 Reagents and conditions: (a) KOH, aq. EtOH, 22 
°C. (b) Ac2O, 4-dimethylaminopyridine (DMAP), NEt3, THF, 0-22 °C or AcCl, NEt3, THF, 0-22 °C. (c) (COCl)2, N,N-
dimethylformamide (DMF), PhMe, 40 °C. (d) MgCl2, NEt3, THF, 4 °C, then acid chloride. (e) aq. NaOH, MeOH, 22 °C. (f) 
HCl in cyclopentylmether ether (CPME), tert-butylmethyl ether, MeOH, 22 °C. (g) BzCl, NEt3, EtOAc, 22 °C, then aq. 
NaOH, MeOH 22 °C. (h) Fe, AcOH, aq. HCl, 40 °C. 
General procedure for the synthesis of 2, 4-diacetoxybenzoic acid  (S15) and 2-acetoxy 4-
methoxybenzoic acid (S18) 
To a solution of 2, 4-dihydroxybenzoic acid (S11) or 2-hydroxy 4-methoxybenzoic acid (S14) (1 eq.) 
in tetrahydrofuran (10 mL/g) was added triethylamine (3.5 eq.), 4-dimethylaminopyridine (0.1 eq.) 
and acetic anhydride (5 eq.) and the reaction was stirred at 22 ºC for 4 h. The reaction mixture was 
acidified with aqueous 1 M HCl to pH 3 and extracted with EtOAc (3 x 100 mL). The combined 
14 
 
organic fractions were washed with brine (100 mL) and dried over Na2SO4. The solvent was removed 
under reduced pressure and the resulting solid was recrystallised from EtOAc to provide the title 
compounds. 
2,4-Diacetoxybenzoic acid (S15)18 
 
Colourless crystalline solid (12.6 g, 82%).  
1H NMR: į(400 MHz, DMSO-d6) 13.14 (br. s, 1H, COOH), 7.98 (d, J=8.6 Hz, 1H, Ar-H), 7.18 (dd, 
J1=8.6, J2=2.3 Hz, 1H, Ar-H), 7.09 (d, J=2.3 Hz, 1H, Ar-H), 2.29 (s, 3H, CH3), 2.24 (s, 3H, CH3).  
13C NMR: į (101 MHz, CDCl3) 169.2 (CO), 168.3 (CO), 168.2 (CO), 155.3 (C), 152.2 (C), 133.5 
(C), 119.5 (CH), 119.3 (CH), 117.5 (CH), 21.2 (CH3), 21.0 (CH3). 
Ȟ
max 
(neat): 2859, 1773, 1680, 1607 cm-1
.
  
LC-MS: m/z 261 (M+Na+, 5%), 179 (100%).  
Rf: (1:1 EtOAc/ heptane) 0.16.  
M.pt.: 135-137 °C (lit. 136-137 °C).18  
2-acetoxy 4-methoxybenzoic acid (S18)19  
 
Colourless crystalline solid (4.96 g, 79%).  
1H NMR: į (400 MHz, DMSO-d6) 12.71 (br. S , 1H, COOH), 7.90 (d, J=8.9 Hz, 1H, Ar-H), 6.93 (dd, 
J1=8.9, J2=2.5 Hz, 1H, Ar-H), 6.77 (d, J=2.5 Hz, 1H, Ar-H), 3.82 (s, 3H, OCH3), 2.23 (s, 3H, CH3).  
13C NMR: į (101 MHz, DMSO-d6) 169.0 (CO), 165.1 (CO), 163.4 (C), 152.2 (C), 133.0 (C), 115.9 
(CH), 111.7 (CH), 109.2 (CH), 55.8 (CH3), 20.9 (CH3). 
Ȟ
max 
(neat): 2936, 1760, 1694, 1611, 1335, 1210 cm-1. 
LC-MS: m/z 211 (M+H+, 2%), 151 (100%).   
Rf: (EtOAc) 0.62.  
M.pt.: 144-115 °C. 
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General procedure for the synthesis of 2-acetoxy 4-chlorobenzoic acid (S16) and 2-acetoxy 4-
nitrobenzoic acid (S17) 
To an ice-cooled solution of 4-chloro-2-hydroxybenzoic acid (S12) or 4-nitro-2-hydroxybenzoic acid 
(S13) (1.0 eq.) in tetrahydrofuran (20 mL) was added triethylamine (3.0 eq.) and acetyl chloride (2.0 
eq.) dropwise and the reaction mixture was stirred at 22 ºC for 16 hours. The reaction mixture was 
acidified with aqueous 2 M HCl to pH 2 and extracted with EtOAc (3 x 15 mL). The combined 
organic fractions were washed with brine (15 mL) and dried over Na2SO4. The solvent was removed 
under reduced pressure and the resulting solid purified as described below. 
2-acetoxy 4-chlorobenzoic acid (S16)20  
 
Purified by recrystallisation from EtOAc to provide the title compound as a colourless crystalline 
solid (0.54 g, 87%). 1H NMR: G (400 MHz, CDCl3) 8.06 (d, J=8.5 Hz, 1H, Ar-H), 7.35 (dd, J1=8.5, 
J2=2.0 Hz, 1H, Ar-H), 7.18 (d, J=2.0 Hz, 1H, Ar-H), 2.35 (s, 3H, CH3). COOH signal not detected. 
13C NMR: G (101 MHz, DMSO-d6) 168.9 (CO), 164.8 (CO), 150.9 (C), 137.6 (C), 132.8 (C), 126.3 
(CH), 124.1 (CH), 123.1 (CH), 20.8 (CH3). Ȟ
max 
(neat): 2680, 1763, 1686 cm-1. m/z: (ES+) 171 (M-
CO2-+H+, 75%), 372 (100%). Rf: (1:1 EtOAc/ heptane) 0.22. M.pt.: 147 °C. (lit.: 133-135 °C).20 
2-acetoxy 4-nitrobenzoic acid (S17)21  
 
Product purified by column chromatography (20-100% EtOAc in heptane) to provide the title 
compound as colourless amorphous solid (0.55 g, 89%). 1H NMR: G (400 MHz, CDCl3) 8.28 (d, 
J=8.6 Hz, 1H, Ar-H), 8.19 (dd, J1=8.6, J2=2.1 Hz, 1H, Ar-H), 8.02 (d, J=2.1 Hz, 1H, Ar-H), 2.39 (s, 3 
H, CH3). COOH signal not detected.13C NMR: G (101 MHz, DMSO-d6) 168.9 (CO), 164.8 (CO), 
150.9 (C), 137.6 (C), 132.8 (C), 126.3 (CH), 124.1 (CH), 123.1 (CH), 20.8 (CH3). Ȟ
max 
(neat): 1768, 
1701, 1523, 1350 cm-1. m/z: (ES+) 211 (M+H+ -16, 100%).22 Rf: (EtOAc) 0.62.  
M.pt.: 146-147 °C.  
2-(tert-butoxycarbonylamino)-3-ethoxy-3-oxopropanoic acid (S10)23 
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To a solution of diethyl 2-((tert-butoxycarbonyl)amino)malonate (S9) (10.0 mL, 39.2 mmol) in 
ethanol (50 mL) was added solid potassium hydroxide (2.25 g, 40.1 mmol). The suspension was 
stirred at 22 °C for 12 hours before concentrating under reduced pressure. The suspension was 
redissolved in 1 M NaHCO3 (75 mL) and washed with EtOAc (2 x 40 mL). The solution was cooled 
to 0 ºC, acidified with solid KHSO4 to pH 2 and extracted with EtOAc (3 x 40 mL). The combined 
organic fractions were washed with brine (20 mL) and dried over Na2SO4. The solvent was removed 
under reduced pressure to provide the title compound as an amorphous colourless solid (7.66 g, 77%).  
1H NMR: G (400 MHz, DMSO-d6) 7.49 (d, J=7.9 Hz, 1H, NH), 4.73 (d, J=7.9 Hz, 1H, CH), 4.15 (q, 
J=7.0 Hz, 2H, CH2), 1.41 (s, 9H, 3xCH3), 1.21 (t, J=7.0 Hz, 3H, CH3). COOH signal not detected. 13C 
NMR:G (101 MHz, DMSO-d6) 167.8 (CO), 167.2 (CO), 156.3 (CO), 78.9 (C), 61.3 (CH2), 57.6 
(CH), 28.1 (CH3), 13.9 (3xCH3). Ȟ
max 
(neat): 3264, 2984, 1756, 1733, 1652 cm-1. m/z: (ES+) 248 
(M+H+, 6%), 148 (100%). M.pt.: 84-85 °C (lit.: 93-95 °C [diethyl ether/ hexane]).23 Rf: (EtOAc) 
0.53. 
General procedure for acid chloride formation  
 
To a suspension of carboxylic acid (1.0 eq.) in anhydrous toluene (10 mL/ g) under a N2 atmosphere 
in a flame dried flask at 22 °C was added (COCl)2 (2.0 eq.) and anhydrous DMF (0.1 eq.). The 
reaction mixture was heated to 40 °C and stirred for 2 hours. The reaction mixture was concentrated 
under reduced pressure and the resulting crude residue was used in the next stage of the synthesis 
without further purification.  
General procedure for the coupling of 2-(tert-butoxycarbonylamino)-3-ethoxy-3-oxopropanoic 
acid (S10) with acid chlorides S19-S22 
 
To an ice-cooled solution of 2-(tert-butoxycarbonylamino)-3-ethoxy-3-oxopropanoic acid (S10) 
(1.0 eq.) in anhydrous tetrahydrofuran (8 mL/ g) under an N2 atmosphere was added triethylamine 
(5.0 eq.) and anhydrous magnesium chloride (3.0 eq.). The resulting slurry was stirred vigorously at 
4 ºC for 2 hours. A solution of the previously prepared crude acid chloride (theoretical amount 1 eq.) 
in anhydrous tetrahydrofuran (5 mL/ mmol) was then added and the resulting suspension stirred for 
2 hours. The reaction mixture was quenched with saturated aqueous ammonium chloride 
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(5 mL/mmol) and extracted with ethyl acetate (3 x 50 mL). The combined organic fractions were 
washed with brine (10 mL) and dried over Na2SO4. The solvent was removed under reduced pressure 
to provide a brown solid which was used in the next stage of the synthesis without further 
purification. 
General procedure for the synthesis of N-Boc aminocoumarin derivatives (S27-S30)17 
To a solution of crude coupling product (S23-S26) (1.0 eq., theoretical) in methanol (10 mL/ g) was 
added aqueous 1 M NaOH (5.0 eq.) and the reaction mixture was stirred at 22 °C for 4 hours. The 
reaction mixture was acidified with 2 M HCl to pH 3 and extracted with EtOAc (3 x 100 mL). The 
combined organic fractions were washed with brine (20 mL), dried over MgSO4 and the solvent 
removed under reduced pressure. The resulting solid was recrystallised from EtOAc to provide the 
title compounds.  
tert-Butyl (4,7-dihydroxy-2-oxo-2H-chromen-3-yl) carbamate (S27)17 
 
Isolated as a pale orange crystalline solid (3.57 g, 58% over 3 stages). 1H NMR: į (400 MHz, DMSO-
d6) 7.79 (br. s, 1H, NH), 7.66 (d, J=8.7 Hz, 1H, Ar-H), 6.79 (dd, J1=8.7, J2=2.2 Hz, 1H, Ar-H), 6.70 
(d, J =2.2 Hz, 1H, Ar-H), 1.44 (s, 9H, 3xCH3). OH signals not detected. 13C NMR: į (101 MHz, 
DMSO-d6) 165.4 (CO), 161.2 (CO), 161.2 (C), 157.9 (C), 154.7 (C), 125.0 (CH), 112.8 (CH), 106.3 
(C), 101.8 (CH), 79.3 (C), 77.3 (C), 28.2 (3xCH3). Ȟ
max 
(neat): 3370, 1612, 1575 cm-1. m/z: (ES+) 294 
(M+H+, 9%), 238 (100%). Rf: (1:1 EtOAc/ heptane) 0.38. M.pt.: 208-210 °C.  
tert-Butyl (7-chloro-4-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (S28)  
 
Isolated as a colourless crystalline solid (0.20 g, 28% over 3 stages). 1H NMR: G (400 MHz, DMSO-
d6) 12.24 (br. s, 1H, OH), 7.98 (br. S. 1H, NH), 7.86 (d, 1H, J=8.5 Hz, Ar-H), 7.59 (d, J=2.0 Hz, 1H, 
Ar-H), 7.43 (dd, J1=8.5, J2=2.0 Hz, 1H, Ar-H), 1.42 (s, 9H, 3xCH3). 13C NMR: G (101 MHz, DMSO-
d6) 160.0 (CO), 157.9 (CO), 154.0 (C), 151.5 (C), 135.8 (C), 124.8 (CH), 124.0 (CH), 115.8 (CH), 
115.2 (C), 103.3 (C), 78.8 (C), 27.7 (3xCH3). Ȟ
max 
(neat): 3287, 1705, 1602 cm-1. m/z: (ES+) 310 
(M+H+, 10%), 236 (100%). HRMS: C14H15ClN2O5 [M+H+] requires 312.0633, found 312.0643. Rf: 
(1:1 EtOAc/ heptane) 0.54. M.pt.: 162 °C. 
18 
 
tert-Butyl (7-nitro-4-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (S29) 
 
 
 
Isolated as a crystalline yellow solid (0.5 g, 70%). 1H NMR G (400 MHz, DMSO-d6) 12.57 (s, 1H, 
OH), 8.22 (d, J=2.2 Hz, 1H, Ar-H), 8.18 (dd, J1=2.2, J2=8.7 Hz, 1H, Ar-H), 8.12 (s, 1H, NH) 8.09 (d, 
J=8.7 Hz, 1H, Ar-H), 1.42 (s, 9H, 3xCH3). 13C NMR G (101 MHz, DMSO-d6) 160.0 (CO), 157.9 (C), 
154.1 (CO), 151.0 (C), 148.9 (C), 125.3 (CH), 121.8 (C), 118.7 (CH), 111.8 (CH), 105.5 (C), 79.1 
(C), 28.1 (3xCH3). Ȟ
max 
(neat): 3286, 1703, 1633, 1523, 1347 cm-1. m/z: (ES+) 323 (M+H+, 4%), 247 
(M-Boc+Na+ 100%). HRMS: C14H15N2O7 [M+H+] requires 323.0874, found 323.0883. Rf: (20% 
EtOAc in heptane) 0.23. M.pt.: decomp. > 210 °C. 
tert-Butyl (7-methoxy-4-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (S30) 
 
Isolated as a colourless crystalline solid (0.68 g, 23%). 1H NMR: G (400 MHz, DMSO-d6) 11.82 (br. 
s, 1H, OH), 7.84 (s, 1H, NH), 7.75 (d, J=8.9 Hz, 1H, Ar-H), 6.96 (m, 2H, Ar-H), 3.86 (s, 3H, CH3), 
1.43 (br. s, 9H, 3xCH3). 13C NMR: G (101 MHz, DMSO-d6) 162.5 (CO), 161.1 (CO), 154.6 (C), 
153.3 (C), 124.7 (CH), 112.1 (CH), 109.1 (C), 100.4 (CH), 78.7 (C), 55.9 (CH3), 28.2 (3xCH3). Two 
C signals not detected. Ȟ
max 
(neat): 3397, 1690, 1611 cm-1. m/z: (ES+) 308 (M+H+, 45%), 252 (100%).  
HRMS: C15H18NO6 [M+H+] requires 308.1129, found 308.1139. Rf: (1:1 EtOAc/ heptane) 0.48. 
M.pt.: 149-150 °C. 
General procedure for synthesis of aminocoumarins (S31-S34)  
 
To an ice cooled solution of the N-Boc protected aminocoumarin (1.0 eq.) in tert-butylmethyl ether 
(TBME) (20 mL/g) and methanol (5 mL/ g) was added HCl in cyclopentylmethyl ether (3 M, 
15.0 eq.) and the mixture stirred at 22 °C for 24 hours. The solvent was removed under reduced 
pressure and the residue triturated with TBME (10 mL). The suspension was filtered to provide the 
title compounds. 
 
3-Amino-4,7-dihydroxy-2H-chromen-2-one hydrochloride (S31)17 
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Isolated as an off-white amorphous solid (1.94 g, 99%). 1H NMR: G (400 MHz, DMSO-d6) 7.78 (d, 
J=8.6 Hz, 1H, Ar-H), 6.75 (dd, J1=8.6, J2=2.3 Hz, 1H, Ar-H), 6.64 (d, J=2.3 Hz, 1H, Ar-H). OH and 
NH2 signals not detected. 13C NMR: G (101 MHz, DMSO-d6) 161.4 (CO), 160.2 (C), 159.6 (C), 153.8 
(C), 125.7 (C), 112.8 (C), 110.3 (CH), 102.3 (CH), 94.3 (CH). Ȟ
max 
(neat): 3336, 1710 cm-1. m/z: 
(ES+) 194 (M+, 100%). Rf: (EtOAc) 0.03. M.pt.: 240-241 °C. 
3-Amino-7-chloro-4-hydroxy-2H-chromen-2-one hydrochloride (S32)  
 
 
Isolated as an off-white amorphous solid (136 mg, 95%). 1H NMR: G (400 MHz, DMSO-d6) 7.88 (d, 
J=8.3 Hz, 1H, Ar-H), 7.64 (br. s. 2H, NH2), 7.43 (s, 1H, Ar-H), 7.32 (d, J=8.3, 1H, Ar-H). OH signals 
not detected.13C NMR: G (101 MHz, DMSO-d6) 159.8 (CO), 152.4 (C), 134.5 (C), 125.6 (CH), 123.2 
(CH), 120.5 (C), 116.0 (CH). Two C signals not detected.Ȟ
max 
(neat): 2900, 1733 cm-1. m/z: (ES+) 212 
(M+, 100%). HRMS: C9H7ClNO3 [M+] requires 212.6092, found 212.212.0109. Rf: (1:1 EtOAc/ 
heptane) 0.08. M.pt.: 241 °C. 
3-Amino-7-nitro-4-hydroxy-2H-chromen-2-one hydrochloride (S33) 
 
Isolated as a pale yellow solid (78 mg, 97%). 1H NMR G (400 MHz, DMSO-d6) 8.37 (br. s., 3H, 
NH3), 8.10 (m, 2H, 2xAr-H), 8.02 (m, 1H, Ar-H). OH signal not detected. 13C NMR G (400 MHz, 
DMSO-d6) 159.6 (CO), 157.8 (C), 154.5 (C), 152.9 (C), 131.9 (C), 128.8 (C), 124.0 (CH), 118.2 
(CH), 111.5 (CH). Ȟ
max 
(neat): 2968, 1668, 1539, 1356 cm-1. m/z: (ES+) 223 (M+, 100%). HRMS: 
C9H7N2O5 [M+] requires 223.0350, found 223.0354. Rf: (EtOAc) 0.06. M.pt.: decomp. >215 °C. 
3-Amino-7-methoxy-4-hydroxy-2H-chromen-2-one hydrochloride (S34) 
 
Isolated as a pale yellow solid (0.35 g, 89%). 1H NMR G (400 MHz, DMSO-d6,) 9.20 (br. s, 4H, OH 
and NH3), 7.93 (d, J=8.2 Hz, 1H, Ar-H), 6.94 (m, 2H, Ar-H), 3.85 (s, 3H, CH3). 13C NMR: G (101 
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MHz, DMSO-d6) 162.4 (CO), 159.9 (C), 153.5 (C), 125.4 (CH), 124.9 (C), 111.7 (CH), 100.6 (CH), 
96.1 (C), 94.8 (C), 55.8 (CH3). Ȟ
max 
(neat): 2914, 1706, 1243, 1194 cm-1. m/z: (ES+) 208 (M+, 100%). 
HRMS: C10H10NO4 [M+] requires 208.0604, found 208.0605. Rf: (EtOAc) 0.04. M.pt.: decomp. 
>250 °C. 
General procedure for the synthesis of aminocoumarin substrates 6 and S1-S4 
To a solution of S31-S34 (1.0 eq.) in EtOAc (12 mL/ mmol) was added benzoyl chloride (5.0 eq.) and 
triethylamine (10.0 eq.). The suspension was stirred at 22 °C for 3 hours before being filtered. The 
filtrate was concentrated under reduced pressure and the residue dissolved in methanol (25 mL). 
Aqueous 1 M NaOH (25 mL, 25.0 mmol) was added and the reaction was stirred at 22 °C for 
12 hours before acidifying to pH 3 with aqueous 2 M HCl. The reaction mixture was extracted with 
EtOAc (3 x 50 mL) and the combined organic fractions were washed with brine (50 mL) and dried 
over Na2SO4. The solvent was removed under reduced pressure and the crude solid washed with 
EtOAc (10 mL) and filtered to provide the title compounds. 
N-(4,7-Dihydroxy-2-oxo-2H-chromen-3-yl) benzamide (6)17 
 
Isolated as a pale yellow amorphous solid (0.43 g, 67%). 1H NMR: į (400 MHz, DMSO-d6) 11.82 
(br. s, 1H, OH), 10.54 (s, 1H, OH), 9.41 (s, 1H, NH), 8.01 (d, J=7.3 Hz, 2H, Ar-H), 7.73 (d, J=8.7 Hz, 
1H, Ar-H), 7.60 (app. t, J=7.3 Hz, 1H, Ar-H), 7.52 (m,   2H, Ar-H), 6.84 (dd, J1 =8.7, J2=2.3 Hz, 1H, 
Ar-H), 6.74 (d, J=2.3 Hz, 1H, Ar-H). 13C NMR: į (101 MHz, DMSO-d6) 166.5 (CO), 161.4 (CO), 
160.8 (C), 160.4 (C), 153.5 (C), 133.9 (C), 131.5 (CH), 128.1 (2xCH) 128.0 (2xCH), 125.0 (CH), 
112.9 (CH), 108.0 (C), 101.9 (CH), 100.1 (C). Ȟ
max 
(neat): 3176, 1665, 1625 cm-1. m/z: (ES+) 298 
(M+H+, 100%). Rf: (1:1 EtOAc/ heptane) 0.31. M.pt.: 283-285 °C (lit.: 283-285 °C).17  
N-(4-Chloro, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S1) 
 
Isolated as a pale yellow amorphous solid (74 mg, 58%). 1H NMR: G (400 MHz, DMSO-d6) 12.30 (s, 
1H, OH), 9.55 (s, 1H, NH), 8.01 (d, J=7.3 Hz, 2H, Ar-H), 7.91 (d, J=8.5 Hz, 1H, Ar-H), 7.64 (d, 
J=2.0 Hz, 1H, Ar-H), 7.59 (d, J=7.3 Hz, 1H, Ar-H), 7.56 - 7.50 (m, 2H, 2xAr-H), 7.47 (dd, J1=2.0, 
J2=8.5 Hz, 1H, Ar-H). 13C NMR: G (101 MHz, DMSO-d6,): 166.4 (CO), 159.9 (CO), 159.2 (C), 152.0 
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(C), 136.5 (C), 133.7 (C), 131.7 (CH), 128.1 (2xCH), 128.0 (2xCH), 125.3 (CH), 124.6 (CH), 116.4 
(CH), 115.4 (C), 103.0 (C). Ȟ
max 
(neat): 3352, 1695, 1623, 701 cm-1. HRMS: C16H11ClNO4 [M+H+] 
requires 316.0371, found 316.0377. Rf: (1:1 EtOAc/ heptane): 0.25. M.pt.: 233 °C. 
N-(4-Nitro, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S2) 
 
Isolated as a pale yellow amorphous solid (40 mg, 63%). 1H NMR: G (400 MHz, DMSO-d6) 9.71 (s, 
1H, NH), 8.27 (d, J=2.1 Hz, 1H, Ar-H), 8.21 (dd, J1=2.1, J2=8.7 Hz, 1H, Ar-H), 8.15 (d, J=8.7, 1H, 
Ar-H), 8.02 (d, J=7.1 Hz, 2H, Ar-H), 7.61 (t, J=7.3 Hz,  1H, Ar-H), 7.53 (t, J=7.6 Hz, 2H, Ar-H). OH 
signal not detected. 13C NMR: G (101 MHz, DMSO-d6) 166.3 (CO), 159.7 (C), 158.2 (CO), 151.1 
(C), 149.0 (C), 133.6 (C), 131.8 (CH), 128.2 (2xCH), 128.0 (2xCH), 125.4 (CH), 121.9 (C), 118.8 
(CH), 111.8 (CH), 105.2 (C). Ȟ
max 
(neat): 1698, 1630, 1524, 1341 cm-1. HRMS: C16H11N2O6 [M+H+] 
requires 327.0612, found 327.0622. Rf: (1:1 EtOAc/ heptane): 0.28. M.pt.: 296 C. 
N-(4-Amino, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S3) 
 
To a suspension of  N-(4-nitro, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (9) (100 mg, 0.307 
mmol) in acetic acid (5 mL) was added iron powder (171 mg, 3.07 mmol). The reaction mixture was 
heated to 50 °C and stirred for 4 hours before concentrating under reduced pressure. The mixture was 
acidified to pH 1 with aqueous 2 M HCl and EtOAc (5 mL) was added. The resulting suspension was 
filtered to provide the title compound as a yellow solid (63 mg, 69%). 1H NMR: G (400 MHz, 
DMSO-d6) 11.48 (s, 1H, OH), 9.33 (s, 1H, NH), 8.00 (d, J=5.7 Hz, 2H, Ar-H), 7.53 (m, 4H, Ar-H), 
6.59 (d, J=7.0 Hz, 1H, Ar-H), 6.43 (s, 1H, Ar-H). NH2 signal not detected.13C NMR: G (101 MHz, 
DMSO-d6) 166.6 (C), 161.0 (CO), 160.7 (CO), 154.0 (C), 153.2 (C), 134.0 (C), 131.5 (CH), 128.1 
(2xCH), 128.0 (2xCH), 124.6 (CH), 111.3 (CH), 104.2 (C), 98.4 (C), 98.2 (CH). Ȟ
max 
(neat): 3349, 
1664, 1608, 1539, 1381 cm-1. HRMS: C16H13N2O4 [M+H+] requires 297.0870, found 297.0879. Rf: 
(1:1 EtOAc/ heptane): 0.2. M.pt.: decomp. >260 °C. 
N-(4-Methoxy, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S4) 
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Isolated as a pale yellow solid (50 mg, 39%). 1H NMR: G (DMSO-d6, 400 MHz) 11.95 (s, 1H, OH), 
9.45 (s, 1H, NH), 8.01 (d, J=7.1 Hz, 2H, Ar-H), 7.81 (d, J=8.7 Hz, 1H, Ar-H), 7.58 (t, J=7.3 Hz, 1H, 
Ar-H), 7.51 (d, J=7.6 Hz, 2H, Ar-H), 7.02 (m, 2H, Ar-H), 3.88 (s, 3H, CH3). 13C NMR: G (101 MHz, 
DMSO-d6) 166.5 (CO), 162.6 (CO), 153.5 (C), 133.9 (CH), 131.6 (CH), 128.2 (2xCH), 128.0 
(2xCH), 124.8 (C), 112.2 (CH), 109.4 (C), 100.5 (CH), 55.9 (CH3). Three C signals not detected.Ȟ
max 
(neat): 3299, 1674, 1609, 1372, 1294, 688 cm-1. HRMS: C17H14NO5 [M+H+] requires 312.0866, 
found 312.0883. Rf: (1:1 EtOAc/ heptane): 0.4. M.pt.: decomp. >240 °C. 
(2R,3R,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3,4-diol (S35)24 
 
To an ice cooled suspension of adenosine (1.00 g, 3.74 mmol) in acetonitrile (10 mL) was added 
pyridine (0.61 mL, 7.48 mmol) and thionyl chloride (1.40 mL, 18.7 mmol) was added dropwise over 
5 minutes. The reaction mixture was stirred at 0 ºC for 3 hours before being warmed to 22 ºC and 
stirred for 16 hours. The resulting precipitate was filtered and dissolved in water/ methanol (5:1). 
Aqueous ammonia (25%, 2.00 mL) was added and the reaction mixture stirred at 22 ºC for 
30 minutes. The solvent was removed under reduced pressure to provide the title compound as a 
colourless amorphous solid (1.05 g, 98%). 1H NMR: G (400 MHz, DMSO-d6) 8.34 (s, 1H, Ar-H,), 
8.16 (s, 1H, Ar-H), 7.29 (s, 2H, NH2), 5.93 (d, J=5.7 Hz, 1H, CH), 5.58 (s, 1H, OH), 5.44 (s, 1H, 
OH), 4.75 (t, J=5.3 Hz, 1H, CH), 4.24 (t, J=4.3 Hz, 1 H, CH), 4.08 (q, J=5.3 Hz, 1H, CH), 3.96 (dd, 
J1=5.1, J2=11.6 Hz, 1H, CH2), 3.84 (dd, J1=6.4,  J2=11.6 Hz, 1H, CH2).  13C NMR: G (101 MHz, 
DMSO-d6) 156.1 (C), 152.7 (CH), 149.4 (C), 139.7 (CH), 119.1 (C), 87.4 (CH), 83.63 (CH), 72.6 
(CH), 71.2 (CH), 44.8 (CH2). m/z: (ES+) 286 (M35Cl + H+, 100%), 288 (M37Cl + H+, 35%). Mpt.: 72 
°C. (lit. 75-80 °C).25 Ȟ
max 
(neat): 3148, 1648, 1601 cm-1. Rf: (EtOAc) 0.20.  
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11 Enzymatic assays using NovO 
All protein concentrations were measured on a Trinean Xpose micro-volume spectrometer, using an 
E1% of 11.308 for NovO. HPLC analysis was carried out on an Agilent 1100 series instrument using 
the following method: 
 
Column:  Waters Xbridge C18 column (50mm x 4.6 mm i.d. 3 ȝPSDFNLQJGLDPHWHUDW Û& 
 
Method:  A = 10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia 
solution. 
B = Acetonitrile. 
Flow rate: 3 mL/ min. 
 
Gradient profile: 
Time (min) % A % B 
0 99 1 
0.1 99 1 
4 3 97 
5 3 97 
Detection:  Detection wavelength of 320 nm used for all aminocoumarin substrates and 
methylated products. 
General Procedure for KIE Measurements 
All reactions were carried out in triplicate in 96 well plate on format 200 uL scale using a 
multichannel pipette for reagent addition and sampling of aliquots. 
 
To a solution of N-(4,7-Dihydroxy-2-oxo-2H-chromen-3-yl) benzamide (6)  (final concentration 0.5 
mM), (2R,3R,4S,5S)-2-(6-amino-9H-purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3,4-diol (ClDA, 
S35) (from a 100 mM stock solution in DMSO, final concentration 2 mM) and methionine, 
methionine-13C or methionine-d3 as appropriate (from a 100 mM stock solution in 250 mM aqueous 
NaOH, final concentration 2.5 mM) in phosphate buffer (50 mM, pH 6.5) was added SalL13,14 (final 
concentration 0.1 mg/ml). The reaction was incubated at 37 °C, 750 rpm for 2 hours. Methyltransfer 
reactions were initiated by the addition of 20 µL NovO (final concentration 0.5 mg/mL) and quenched 
after 3 minutes by transferring 50 µL of the reaction into a preheated vial and incubated at 97 °C for 
10 minutes before clarifying by centrifugation (15 minutes, 13.2k rpm, 4 °C). The supernatant was 
transfered to an HPLC insert vial and 5 uL injected directly onto the HPLC according to the above 
method. % conversion was calculated by the ratio of area/area% of starting material (RT = 2.528 min) 
to product (RT=2.664 min). 
12 Methyl transfer assay using NovO or NovO mutants 
To a 1.5 mL Eppendorf vial containing in sodium phosphate buffer (50 mM, pH 6.5 to a total volume 
of 0.5 mL), 100 µM substrate (from a 50 mM stock solution in DMSO), 2 mM SAM (from a 20 mM 
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stock solution in sodium phosphate buffer) and bovine serum albumin (0.1 mg/mL, taken from 
2 mg/mL stock solution in sodium phosphate buffer) was added 250 µg purified enzyme (final 
concentration = 1.9 µM) in SEC buffer (see above) containing 40% glycerol. Reactions were 
incubated at 35 °C, 1000 rpm using a thermomixer and quenched after 24 hours by heating to 80 °C 
for 15 minutes. Samples were  cooled to 4 °C for 10 minutes, clarified by centrifugation (10 minutes, 
13 200 rpm, 4 °C) and 5 µL injected directly onto the HPLC instrument for analysis. HPLC analysis 
was carried out on an Agilent 1100 series instrument using the following method: 
 
Column:  Waters Xbridge C18 column (50mm x 4.6 mm i.d. 3 ȝPSDFNLQJGLDmeter) at 40 Û& 
 
Method:  A = 10 mM ammonium bicarbonate in water adjusted to pH 10 with ammonia 
solution. 
B = Acetonitrile. 
Flow rate: 3 mL/ min. 
 
Gradient profile: 
Time (min) % A % B 
0 99 1 
0.1 99 1 
4 3 97 
5 3 97 
Detection:  Detection wavelength of 320 nm used for all aminocoumarin substrates and 
methylated products. 
Conversions were calculated by area/area% conversion from starting material to methylated product 
(Figure S10).  
 
Figure S10. Exemplar HPLC spectrum for the MT assay used to determine the catalytic activity of NovO WT and mutants. 
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13 Analysis of NovO mutants by methyl transfer assay 
Assays were carried out as described in Section 12. Percentage (%) conversion calculated by HPLC 
area/area% observed for each mutant (Table 1). 
 
Mutant % Conversion after 24 h 
WT 98 
F14M 19 
F14L 30 
R24F 15 
R116L 1 
R116K <1 
N117A <1 
H120A* 0 
H120N <1 
R121L <1 
R121Q/G108D <1 
Y216F 20 
Control** 0 
Table 2. Analysis of NovO WT and mutant library. Reagents and conditions: (a) NovO WT or mutant, SAM, bovine serum 
albumin, 50 mM sodium phosphate buffer pH 6.5, 35 °C, 24 h. *Cell lysate used due to poor solubility of H120A mutant. 
**Reactions were carried out next to a negative control in which no MT was added. 
14 Preparative scale methylation of 6 using NovO 
N-(4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)benzamide17 
 
To a 40 mL aliquot of E. coli cell lysate from the overexpression of NovO in phosphate buffer 
(50 mM, pH 6.5, resupended at 10 mL/g cell pellet) was added bovine serum albumin (final 
concentration 1 mg/ mL), SAM (72.0 mg in 2.5 mL phosphate buffer, 0.126 mmol) and N-(4,7-
dihydroxy-2-oxo-2H-chromen-3-yl)benzamide 6 (20 mg in 2.5 mL dimethyl sulfoxide, 0.084 mmol). 
The reaction was incubated at 35 °C, 350 rpm for 24 hours, before adding a further portion of SAM 
(72.0 mg in 1 mL phosphate buffer, 0.126 mmol). The reaction mixture was incubated for a further 16 
hours at 35 °C, 350 rpm before adding aqueous 5 M HCl to pH 2 and clarifying the suspension by 
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centrifugation (4000 rpm, 20 min). HPLC conversion at end of reaction: 90%. The supernatant was 
concentrated by lyophilisation and the residue purified by mass-directed automated purification 
(MDAP). The product was precipitated by the addition of MeOH (5 mL) and filtered to 
provide the title compound as a pale yellow amorphous solid (14 mg, 67%). 1H NMR: G (400 
MHz, DMSO-d6) 11.71 (br. s., 1H, OH), 10.42 (s, 1H, OH), 9.41 (s, 1H, NH), 8.01 (d, J=7.4 Hz, 2H, 
Ar-H), 7.48-7.62 (m, 2x2H, Ar-H), 6.89 (d, J=8.7 Hz, 1H, Ar-H), 2.18 (s, 3H, CH3). 13C NMR: G 
(101 MHz, DMSO-d6) 166.5 (CO), 160.8 (CO), 160.5 (C), 159.1 (C), 151.5 (C), 133.9 (C), 131.6 
(CH), 128.1 (2xCH), 128.0 (2xCH), 121.5 (CH), 111.8 (CH), 110.4 (C), 107.9 (C), 99.9 (C), 8.1 
(CH3). Ȟ
max 
(neat): 3215, 1567, 1534, 1369, 1312 cm-1. HRMS: C17H14NO5 [M+H+] requires 
312.0868, found 312.0866. Rf: (EtOAc): 0.28. M.pt.:. 310-312 °C. 
15 General procedure for the preparation of NovO mutants by Site-Directed 
Mutagenesis 
Site-directed mutagenesis (SDM) was accomplished by a modified QuickChange protocol using 
primers bearing desired mutations (see below). Colonies containing the desired mutation were 
identified by gene sequencing using T7 forward and reverse primers. Colonies bearing the desired 
mutation were amplified using a Qiagen Miniprep NLW DFFRUGLQJ WR WKHPDQXIDFWXUHU¶V LQVWUXFWLRQV
eluting with 100 µL elution buffer. The gene sequence for all mutants was confirmed by gene 
sequencing using the gene sequencing primers detailed below. 
SDM 3ULPHUV¶WR¶ 
F14M fwd GGTTCCGAAGCAGAAGCAATGCACCGCATGGGCTCG 
F14M rev CGAGCCCATGCGGTGCATTGCTTCTGCTTCGGAACC 
F14L fwd GGTTCCGAAGCAGAAGCACTCCACCGCATGGGCTCG 
F14L rev CGAGCCCATGCGGTGGAGTGCTTCTGCTTCGGAACC 
R24M fwd GGCTCGCAAGCATCGCACATGTATGACGAATTTGTT 
R24M rev AACAAATTCGTCATACATGTGCGATGCTTGCGAGCC 
R24F fwd GGCTCGCAAGCATCGCACUTCTATGACGAATTTGTT 
R24F rev AACAAATTCGTCATAGAAGTGCGATGCTTGCGAGCC 
H120F fwd GTGAGTCGTAATGCCTTTTTCCGTCTGACCCGCCTG 
H120F rev CAGGCGGGTCAGACGGAAAAAGGCATTACGACTCAC 
H120N fwd GTGAGTCGTAATGCCTTTAACCGTCTGACCCGCCTG 
H120N rev CAGGCGGGTCAGACGGTTAAAGGCATTACGACTCAC 
H120A fwd GTGAGTCGTAATGCCTTTGCCCGTCTGACCCGCCTG 
H120A rev CAGGCGGGTCAGACGGGCAAAGGCATTACGACTCAC 
N117A fwd CTGGTCGTGAGTCGTGCTGCCTTTCACCGTCTGACC 
N117A rev GGTCAGACGGTGAAAGGCAGCACGACTCACGACCAG 
R121Q fwd CGTAATGCCTTTCACCAGCTGACCCGCCTGCCG 
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R121Q rev CGGCAGGCGGGTCAGCTGGTGAAAGGCATTACG 
R121L fwd CGTAATGCCTTTCACCTTCTGACCCGCCTGCCG 
R121L rev CGGCAGGCGGGTCAGAAGGTGAAAGGCATTACG 
Y216F fwd GTGTGGATCGATGACCAAGGCTTCGGTGTGCCGACGGTT 
Y216F rev AACCGTCGGCACACCGAAGCCTTGGTCATCGATCCACAC 
Gene sequencing primers ¶WR¶ 
NovO 1 fwd CAATCACGGGTTCCGAAG 
NovO 1 rev CTTCGGAACCCGTGATTG 
NovO 2 fwd CGGTATTGCAGATGGCC 
NovO 2 rev GGCCATCTGCAATACCG 
NovO 3 fwd GTCGATCTGAGCGAAGAC 
NovO 3 rev GTCTTCGCTCAGATCGAC 
NovO 4 fwd AGGCATGGAAGATCTGG 
NovO 4 rev CCAGATCTTCCATGCCT 
NovO 5 fwd GCTGCGCCTGGCTAAAC 
NovO 5 rev GTTTAGCCAGGCGCAGC 
NovO 6 fwd CATGGGTTACGTTCCTG 
NovO 6 rev CAGGAACGTAACCCATG 
NovO 7 fwd CTATGCGCCGCGTCTGG 
NovO 7 rev CCAGACGCGGCGCATAG 
NovO 8 fwd GTGCCGACGGTTAAATG 
NovO 8 rev CATTTAACCGTCGGCAC 
 
Gene synthesis and cloning 
The gene for NovO with a C-terminal 6-His tag was synthesized by GenScript with codon 
optimization and subcloned into a pET26b(+) plasmid using NdeI and XhoI restriction sites. The 
plasmid was received from GenScript in the lyophilised form and was resuspended in 40 µL water. 
E.coli TOP10 competent cells were transformed using the heat shock method with 5 µL of DNA 
solution. Transformants were plated on LB agar containing 50 µg/ mL NDQDP\FLQDQGJURZQDWÛC 
overnight. Colonies were inoculated into 10 mL LB media containing 50 µg/ mL kanamycin and 
JURZQ RYHUQLJKW DW  ÛC. The DNA was then extracted and purified using a Qiagen Miniprep kit 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVHOXWLQJwith 100 µL elution buffer.  
General procedure for the expression of NovO and NovO mutants 
The plasmid pET26b(+)-NovO was transformed into E. coli BL21 DE3 competent cells (Invitrogen) 
for protein expression. Transformants harbouring the plasmids were grown at 37 Û&LQ/%PHGLXP
supplemented with 50 µg/ mL kanamycin and 1% glucose overnight. This seed culture was used to 
inoculate Magic Media supplemented with kanamycin (final concentration of 50 µg/ mL) and 
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Component B (5% v/v) using 2% inoculant. The cultures were incubated at 30 °C, 200 rpm and 
grown to an OD of ~2 before the incubating at 18 °C, 200 rpm overnight. The cells were harvested by 
centrifugation (4400 rpm, 4 °C, 20 minutes), the supernatant discarded and the cell pellets stored at -
80 °C for further use. 
16 Preparation of SelMet labeled NovO 
The plasmid pET26b(+)-NovO was transformed into E. coli BL21 DE3 competent cells (Invitrogen) 
for protein expression. Transformants harbouring the plasmids were grown at 37 °C in 100 mL LB 
medium supplemented with 50 µg/ mL kanamycin and 1% glucose for 7 hours at 37 °C, 240 rpm. 
This seed culture was used to inoculate 1 L Modified Terrific Broth (MTB) supplemented with 
kanamycin (final concentration of 50 µg/ mL) and 4% glucose, using 2% inoculant. The culture was 
grown overnight at 30 °C, 180 rpm. The culture was spun (4700 rpm, 22 °C, 30 minutes) and the 
supernatant was discarded. The pellet was resuspended in G1X minimal media supplemented with 
sorbitol (440 mM) betaine (1.5 mM) glycerol (1% v/v) kanamycin (50 µg/ mL) and amino acids 
threonine, lysine, phenylalanine (each at 100 µg/ mL) and leucine, isoleucine, valine and 
selenomethionine (each at 50 µg/mL). The culture was incubated at 37 °C, 180 rpm for 30 minutes 
and then at 18 ºC, 180 rpm for 30 minutes before inducing with LVRSURS\O ȕ-D-1-
thiogalactopyranoside (IPTG) (final concentration of 100 µM) and incubating overnight at 18 °C, 
180 rpm. The cells were harvested by centrifugation (4400 rpm, 4 °C, 20 minutes), the supernatant 
discarded and the cell pellets stored at -80 °C for further use. 
17 Purification of SelMet NovO and NovO mutants 
General procedure for the purification of NovO, NovO mutants and SelMet NovO by affinity 
chromatography 
Binding Buffer (Buffer A): 50 mM Tris-HCl, 300 mM NaCl, pH 8.0 
Elution Buffer (Buffer B): 50 mM Tris-HCl, 300 mM NaCl, 500 mM imidazole, pH 8.0 
 
The cell pellet (~30 g) was resuspended in 200 mL binding buffer and the cells lysed by sonication on 
ice using a 19 mm probe for 5 minutes (9.9 s on, 9.9 s off) at 40% intensity. The resulting cell lysate 
was separated by centrifugation (100 000 g, 4 °C, 90 minutes) and the supernatant collected. A 5 mL 
HisTRAP HP column (GE Healthcare 17-5248-02) was washed with 10 column volumes (CV) of 
elution buffer before being equilibrated with binding buffer. The clear cell lysate was loaded onto the 
column and eluted as follows: 
Step 1: 0-20 mM imidazole (0-4% elution buffer) for 10 CV 
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Step 2: 20-50 mM imidazole (4-10% elution buffer) for 10 CV 
Step 3: 50-500 mM imidazole (10-100% elution buffer) for 10 CV 
 
 
Figure S7. SDS-PAGE gel from purification of NovO mutant library. Theoretical mass of NovO WT: 26.23 KDa. 
General procedure for the purification of NovO by Size Exclusion Chromatography (SEC) 
SelMet labeled protein was additionally purified by SEC according to following procedure (SEC 
buffer: 100 mM Tris-HCl, 150 mM NaCl, 5% glycerol, pH 8): 
A HiLoad 26/60 320 mL Superdex 75 prep grade SEC Column was equilibrated with SEC buffer and 
loaded with 10 mL of the pooled fractions from the affinity chromatography pool. The column was 
eluted over with SEC buffer, collecting 2 mL fractions, which were analysed by SDS-PAGE. 
Fractions containing NovO were concentrated as required using an Amicon Ultra 15 centrifugal filter 
with a 10 KDa retention limit. 
 
Figure S9. SDS-PAGE gel from purification of SelMet NovO. Theoretical mass of NovO WT: 26.23 KDa. 
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22K
250K
148K
98K
64K
50K
36K
 1    2      3    4       5      6    7    8    9   10  11  Lanes 
1 ʹ Marker 
2 ʹ Load 
3 ʹ Non-absorbed fraction 
4 ʹ Wash 
5 ʹ HisTrap pool 
6 ʹ HisTrap pool concentrate 
7 ʹ Blank 
8 ʹ Blank 
9 ʹ SEC pool 
10 ʹ SEC pool concentrate 
11 ʹ Blank 
12 ʹ Marker 
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18 1H and 13C NMR Spectra of Novel Compounds 
tert-Butyl (7-chloro-4-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (S28)  
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tert-Butyl (7-nitro-4-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (S29) 
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tert-Butyl (7-methoxy-4-hydroxy-2-oxo-2H-chromen-3-yl) carbamate (S30) 
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3-Amino-7-chloro-4-hydroxy-2H-chromen-2-one hydrochloride (S32)  
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3-Amino-7-nitro-4-hydroxy-2H-chromen-2-one hydrochloride (S33) 
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3-Amino-7-methoxy-4-hydroxy-2H-chromen-2-one hydrochloride (S34) 
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N-(4-Chloro, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S1) 
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N-(4-Nitro, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S2) 
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N-(4-Amino, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S3) 
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N-(4-Methoxy, 7-hydroxy-2-oxo-2H-chromen-3-yl) benzamide (S4) 
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N-(4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-yl)benzamide17 
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